Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 16/20 | 0.56 |
| ▸ | TACR2 | P21452 | 16/20 | 0.56 |
| ▸ | TAC3 | Q9UHF0 | 6/20 | 0.56 |
| ▸ | TACR3 | P29371 | 4/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397491 | 0.87 | SLC6A9 (0.41) | TACR1TACR2TAC3 | |
| SCHEMBL1971144 | 0.82 | USP30 (0.51) | TACR1TACR2TAC3TACR3RORC | |
| SCHEMBL1968714 | 0.77 | TACR1 (0.60) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL1972502 | 0.76 | TACR1 (0.59) | TACR1TACR2TAC3TACR3RORC | |
| SCHEMBL26404206 | 0.75 | TACR1 (0.61) | TACR1TACR2TAC3TACR3RORC | |
| SCHEMBL1969048 | 0.75 | TACR1 (0.61) | TACR1TACR2TAC3TACR3RORC | |
| SCHEMBL13801317 | 0.75 | TACR1 (0.61) | TACR1TACR2TAC3TACR3RORC | |
| SCHEMBL4144151 | 0.75 | TACR1 (0.61) | TACR1TACR2TAC3TACR3RORC | |
| SCHEMBL4149078 | 0.75 | TACR2 (0.78) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL4149072 | 0.75 | TACR2 (0.78) | TACR1TACR2TAC3TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8592454-B2 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | TACR1 13/4885TACR2 29/4885TAC3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.